208 related articles for article (PubMed ID: 17336978)
1. Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome.
Romualdi D; Giuliani M; Draisci G; Costantini B; Cristello F; Lanzone A; Guido M
Fertil Steril; 2007 Jul; 88(1):131-8. PubMed ID: 17336978
[TBL] [Abstract][Full Text] [Related]
2. Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome.
Garmes HM; Tambascia MA; Zantut-Wittmann DE
Gynecol Endocrinol; 2005 Dec; 21(6):317-23. PubMed ID: 16390779
[TBL] [Abstract][Full Text] [Related]
3. ACTH stimulation test in lean polycystic ovary syndrome patients with insulin resistance.
Uncu G; Ozyurek SE; Uncu Y
Fertil Steril; 2007 Sep; 88(3):670-4. PubMed ID: 17451692
[TBL] [Abstract][Full Text] [Related]
4. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R
Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
[TBL] [Abstract][Full Text] [Related]
5. Impact of glycemic variations on the regulation of androgen metabolism in obese women with polycystic ovary syndrome.
Ludwig AK; Goharian LG; Dietze T; Tauchert S; Rudolf S; Diedrich K; Schweiger U; Oltmanns KM
Fertil Steril; 2009 Jul; 92(1):271-6. PubMed ID: 18692843
[TBL] [Abstract][Full Text] [Related]
6. Administration of exogenous ghrelin in obese patients with polycystic ovary syndrome: effects on plasma levels of growth hormone, glucose, and insulin.
Guido M; Romualdi D; De Marinis L; Porcelli T; Giuliani M; Costantini B; Lanzone A
Fertil Steril; 2007 Jul; 88(1):125-30. PubMed ID: 17276431
[TBL] [Abstract][Full Text] [Related]
7. Effect of metformin on the growth hormone response to growth hormone-releasing hormone in obese women with polycystic ovary syndrome.
Guido M; Romualdi D; Giuliani M; Suriano R; Tienforti D; Costantini B; Lanzone A
Fertil Steril; 2005 Nov; 84(5):1470-6. PubMed ID: 16275246
[TBL] [Abstract][Full Text] [Related]
8. Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis.
Azziz R; Black V; Hines GA; Fox LM; Boots LR
J Clin Endocrinol Metab; 1998 Jul; 83(7):2317-23. PubMed ID: 9661602
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome.
De Leo V; Morgante G; Piomboni P; Musacchio MC; Petraglia F; Cianci A
Fertil Steril; 2007 Jul; 88(1):113-7. PubMed ID: 17418832
[TBL] [Abstract][Full Text] [Related]
10. [Androgen response in women with polycystic ovary syndrome and hyperinsulinemia during stimulation with corticotrophin and inhibition with dexamethasone].
Espinosa de los Monteros A; Guerra de la Garza A; Barrón J; Parra A
Rev Invest Clin; 1996; 48(4):267-73. PubMed ID: 8966389
[TBL] [Abstract][Full Text] [Related]
11. Adrenal function under long-term raloxifene administration.
Genazzani AR; Lombardi I; Borgioli G; di Bono I; Casarosa E; Gambacciani M; Palumbo M; Genazzani AD; Luisi M
Gynecol Endocrinol; 2003 Apr; 17(2):159-68. PubMed ID: 12737677
[TBL] [Abstract][Full Text] [Related]
12. [Role of hyperinsulinemia in pathogenesis of polycystic ovary syndrome and treatment by reduction of insulin secretion].
Wang A; Li M; Lu C
Zhonghua Fu Chan Ke Za Zhi; 1998 Dec; 33(12):731-4. PubMed ID: 10806662
[TBL] [Abstract][Full Text] [Related]
13. Increased secretion of amylin in women with polycystic ovary syndrome.
James S; Moralez J; Nagamani M
Fertil Steril; 2010 Jun; 94(1):211-5. PubMed ID: 19338997
[TBL] [Abstract][Full Text] [Related]
14. Evidence of a disturbance of the hypothalamic-pituitary-adrenal axis in polycystic ovary syndrome: effect of naloxone.
Lanzone A; Guido M; Ciampelli M; Fulghesu AM; Pavone V; Proto C; Caruso A; Mancuso S
Clin Endocrinol (Oxf); 1996 Jul; 45(1):73-7. PubMed ID: 8796141
[TBL] [Abstract][Full Text] [Related]
15. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
16. Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism.
Romualdi D; De Marinis L; Campagna G; Proto C; Lanzone A; Guido M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):562-7. PubMed ID: 18248643
[TBL] [Abstract][Full Text] [Related]
17. Failure of the homeostatic model assessment calculation score for detecting metabolic deterioration in young patients with polycystic ovary syndrome.
Fulghesu AM; Angioni S; Portoghese E; Milano F; Batetta B; Paoletti AM; Melis GB
Fertil Steril; 2006 Aug; 86(2):398-404. PubMed ID: 16769061
[TBL] [Abstract][Full Text] [Related]
18. Effects of flutamide on pituitary and adrenal responsiveness to corticotrophin releasing factor (CRF).
De Leo V; la Marca A; Lanzetta D; Cariello PL; D'Antona D; Morgante G
Clin Endocrinol (Oxf); 1998 Jul; 49(1):85-9. PubMed ID: 9797851
[TBL] [Abstract][Full Text] [Related]
19. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
[TBL] [Abstract][Full Text] [Related]
20. Obesity differentially affects serum levels of androstenedione and testosterone in polycystic ovary syndrome.
Moran C; Renteria JL; Moran S; Herrera J; Gonzalez S; Bermudez JA
Fertil Steril; 2008 Dec; 90(6):2310-7. PubMed ID: 18163993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
